Klinik am Ring
With bone scans, metastasis can be identified in the bones before they become visible in an x-ray.
Bone scintigraphy, commonly referred to as bone scan (also skeletal scintigraphy) is a special nuclear medical method for examination that measures the traces of radioactive agent, e.g. previously administered radioactive medication accumulated inside the bone. The distribution patterns and the amount of tracers allow for indications of an increased metabolism, such is generally found with metastasic prostate cancer.
In contrast to radiological examination procedures (CT/MRT), which primarily show the changes of the bone structure, scintigraphy primarily provides information about abnormal changes in the bone metabolism. Abnormal scintigrafic findings are, however, no evidence for metastasis, since they can also occur as a result of benign bone disease or deterioration of the joints (arthritis).
Bone scintigraphy should always be performed to rule out bone metastasis in all patients with prostate specific antigen level (PSA) above 20 ng/ml, or with aggressive tumor types (Gleason score above 7).
Sexualstörungen nach der radikalen Entfernung der Prostata häufig aber wenig beachtet. Viele Patienten fürchten nach einer Prostatakrebs-OP den Verlust eines erfüllten Sexuallebens.
“Men diagnosed with prostate cancer are still not thoroughly informed about urinary incontinence as a consequence of surgery prior to undergoing the procedure,” complains Dr. Stephan Neubauer, Urologist at the West German Prostate Center.
"PSA testing is useless and sometimes even dangerous“ ? a statement that is frequently incorrectly transported by the media, lately even in the broadcast of the RBB Politmagazine Kontraste "Early detection for prostate cancer: The business of fear."
Internal radiation – more effective, safe, and cost efficient than radical surgery
Urinary incontinence, erectile dysfunction, impotence? Especially for younger patients with prostate cancer the expected adverse effects play crucial role in the selection of therapy.
Who benefits from a treatment and who does not?
Is it worthwhile for 75-year-old men to undergo a therapy of prostate cancer or are the elderly better off with a wait and see approach?